Medical Uses
Mepron (atovaquone) oral suspension is a quinone antimicrobial drug used for:
- Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprimsulfamethoxazole (TMP-SMX).
- Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX.
Limitations of Use: This oral suspension has not been studied for treating severe PCP (alveolar-arterial oxygen diffusion gradient [(Aa)DO2] >45 mm Hg), and its efficacy in subjects failing therapy with TMPSMX has also not been studied.
Recommended Dosage:
Prevention of P. jirovecii Pneumonia: The recommended oral dosage of Mepron is 1,500 mg (10 mL) once daily administered with food.
Treatment of Mild-to-Moderate P. jirovecii Pneumonia: The recommended oral dosage of Mepron is 750 mg (5 mL) twice daily (total daily dose = 1,500 mg) administered with food for 21 days.
Use Mepron oral suspension with food to avoid low plasma atovaquone concentrations that may limit response to therapy.